Investigating the role of Reelin in Fragile X syndrome
Reelin and Fragile X Syndrome
This study is looking at how a protein called Reelin might help improve symptoms of Fragile X syndrome, which affects thinking and behavior, and it hopes to find new ways to treat this condition through gene therapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of South Florida NIH-funded |
| Lab location | 1 site (Tampa, United States) |
| Project ID | NIH-11073783 on NIH RePORTER |
What this research studies
This research explores how Reelin, a signaling protein, affects Fragile X syndrome (FXS), which is the most common inherited cause of intellectual disability. FXS presents with various symptoms, including cognitive impairment, anxiety, and hyperactivity. The study aims to understand the underlying mechanisms of FXS and evaluate the potential of using gene therapy to restore synaptic function, which could lead to new treatment options. By focusing on the role of Reelin, the research seeks to uncover novel therapeutic strategies that could improve the lives of individuals with FXS.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Fragile X syndrome, particularly those experiencing cognitive and behavioral challenges.
Not a fit: Patients without a diagnosis of Fragile X syndrome or those with other unrelated intellectual disabilities may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapeutic approaches that improve cognitive and behavioral outcomes for patients with Fragile X syndrome.
How similar studies have performed: While gene therapy approaches for FXS have been explored, the specific focus on Reelin as a therapeutic target is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
Tampa, United States
- University of South Florida — Tampa, United States (Active)
Researchers
- Principal investigator: Nash, Kevin Ron — University of South Florida
- Study coordinator: Nash, Kevin Ron
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.